The Latest Breaking News from FDA

As the biotech industry rebounds from recent challenges, a favorable regulatory environment and groundbreaking scientific advancements are creating investment opportunities, particularly in companies with robust clinical pipelines and promising early-stage data.

This tiny stock could soar more than 400%, according to Wall Street.

Federal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD

Skin cancer is the most common cancer in the US and while sunscreen abounds in aisles, many aren’t applying it correctly

A growing number of Americans have reason to question the safety and efficacy of U.S. sunscreens.

The biotech industry's future is promising, driven by advanced technologies like AI and VR, the rising popularity of personalized treatments, and increased R&D spending. Let's analyze the investment prospects of biotech stocks Amgen (AMGN), United Therapeutics (UTHR), and Gilead Sciences (GILD) as potential breakthroughs emerge. Read more.

Humacyte is a pre-revenue biotech company that has delivered outsized gains to shareholders in 2024. But is the small-cap stock a good buy right now?

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

FDA advisers this week will scrutinize what could become the first approved psychedelic drug.

Smart rings are getting more popular by the year, but there are a few things keeping them from really breaking into the mainstream. Here's my wishlist for what these smart rings could really use.

The use of the drugs in treating low mood has sparked debate, not least about the necessity of a hallucinogenic experience. But a new discovery may provide an answer